Brickell Biotech Inc
BBI.OQ- Latest Trade
- trading higher0.13USD
- Change
- 0
- % Change
0.00%
- Day Range
- -- - --
- 52-Week Range
- 0.11 - 1.03
As of Jul 1 2022. Values delayed up to 15 minutes
- Previous Close
- 0.13
- Open
- 0.00
- Volume
- 11,754.00
- 3 Month Average Trading Volume
- 171.06
- Shares Out (Mil)
- 119.42
- Market Cap
- 20.54
- Forward P/E
- -0.92
- Dividend Yield
- -99,999.99
Key Statistics
1.5 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 42.88
- Price To Book (Quarterly)
- 1.28
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -175.22
- Return On Equity (TTM)
- -133.73
2021 (millions USD)
About Brickell Biotech Inc
Company Information
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.
Address
5777 Central Ave Ste 102BOULDER, CO
80301-2870
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Reginald L. Hardy
- Chairman of the Board, Co-Founder
- Robert B. Brown
- Chief Executive Officer, Director
- Andrew D. Sklawer
- Co-Founder, Chief Operating Officer, Secretary
- Albert N. Marchio
- Chief Financial Officer, Chief Accounting Officer
- David R. McAvoy
- Chief Compliance Officer, General Counsel
- Deepak Chadha
- Chief Research and Development Officer
- Monica Luchi
- Chief Medical Officer
- Gary A. Lyons
- Independent Director
- Vijay B. Samant
- Independent Director
- Dennison T. Veru
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,804.80 | 0.04%Positive |
| Copper | 677.00 | 2.47%Negative |
| Brent Crude Oil | 111.60 | 2.36%Positive |
| CBOT Soybeans | 1,626.00 | 2.93%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,774.93 | 0.28%Negative |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes